Syngene International Limited

SYNGENE

INE398R01022

Biotechnology & Medical Research

Market Closed - NSE India S.E. Other stock markets 05:19:43 11/07/2025 pm IST			5-day change	1st Jan Change
626.15 ^INR	-1.28%		-2.80%	-27.06%

16/06	Syngene Gets Voluntary Action Indicated Classification from US FDA for Biocon Park Facility	MT
16/06	Syngene International Facility Cleared by US FDA with Zero Observations After Inspection	MT

Syngene International Gets Establishment Inspection Report From USFDA

Published on 13/06/2025 at 20:07

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Syngene International Limited

Syngene Gets Voluntary Action Indicated Classification from US FDA for Biocon Park Facility	16/06	MT
Syngene International Facility Cleared by US FDA with Zero Observations After Inspection	16/06	MT
Syngene International Gets Establishment Inspection Report From USFDA	13/06	RE
Syngene International Limited Appoints Vinita Bali as Additional Non-Executive Non Independent Director, Effective July 22, 2025	06/06	CI
Jefferies Adjusts Syngene International's Price Target to INR650 From INR860, Keeps at Hold	25/04	MT
Syngene International Limited, Q4 2025 Earnings Call, Apr 24, 2025	24/04
Syngene International Limited Announces Resignation of Priyadarshini Mahapatra, Head Legal, Company Secretary & Compliance Officer, Effective June 9, 2025	23/04	CI
Syngene International Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	23/04	CI
Syngene International Appoints CEO	02/04	MT
Syngene International Limited Appoints Peter Bains as Chief Executive Officer	01/04	CI
Syngene International Limited Appoints Peter Bains as Managing Director	01/04	CI
Syngene International Says National Faceless Assessment Centre Drops Penalty Proceedings For 33.6 Million Rupees	28/03	RE
Syngene International Gets Tax Demand Order For 2.4 Million Rupees	26/03	RE
O2 Renewable Energy Ii Private Limited announced that it expects to receive INR 65 million in funding from Syngene International Limited	24/03	CI
Syngene International Unit Completes $36.5 Million Acquisition of US Biologics Site	20/03	MT
Emergent BioSolutions Completes Sale of Baltimore-Bayview Facility to Syngene International	20/03	MT
Emergent Biosolutions finalizes sale of Baltimore-Bayview manufacturing site to Syngene International	20/03	RE
Syngene International Limited completed the acquisition of Baltimore-Bayview drug substance manufacturing facility to Emergent BioSolutions Inc. from Emergent BioSolutions Inc. for $36.5 million.	19/03	CI
Syngene International to Invest Up to $56 Million in US Subsidiary	11/03	MT
India's Syngene International acquires first US biologics facility for $36.5 mln	10/03	RE
Syngene International To Invest Up To USD 56 Million In Syngene USA	10/03	RE
Syngene International Acquires First Biologics Site In USA	10/03	RE
India's Syngene International acquires first US biologics facility for $36.5 mln	10/03	RE
Emergent to Sell Baltimore-Bayview Facility for $36.5 Million	10/03	MT
Syngene International Limited entered into an agreement to acquire Baltimore-Bayview drug substance manufacturing facility to Emergent BioSolutions Inc. from Emergent BioSolutions Inc. for $36.5 million.	10/03	CI

Chart Syngene International Limited

Duration

Period

SYNGENE: Dynamic Chart

Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development (R&D), current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. Its business divisions include discovery services, R&D centers, development services, and manufacturing services. It serves the pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. It operates multi-modal biologics manufacturing facility.

Employees

6,533

Sector

Biotechnology & Medical Research

Calendar

23/07 - Q1 2026 Earnings Release

More about the company